Wikipedia -WSS

Wikipedia

author：focus 2025-09-03 11:52:16 - browse：56

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Twill hunts for pharma partner to market its depression app

leisure time

WSS

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Mega Millions pot grows to $1.25 billion after no winner

NIH launches clinical trials and new research office for long Covid

Biden administration sends mixed signals on US soldier who crossed into North Korea

EQRx, failed developer of low

explore

Wikipedia

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

What does generative AI mean for health care? We asked experts

EQRx, failed developer of low

Cancer drug shortages should be causing more outrage

A strong 6.5

Wildfire smoke exposes gaps in outdoor worker protections

Scientists inch closer to single

In Memoriam: Notable people who died in 2023

What the US credit downgrade means for the economy, your finances

focus

New safety details link Apellis eye drug to rare cases of blindness

Why you get paid to donate plasma but not blood

More hospitals are billing patients as online messages surge

Scientists inch closer to single

Flagship, Pfizer team up in deal worth up to $7 billion

BridgeBio heart drug succeeds in pivotal study

leisure time

entertainment

explore

knowledge